NEWS Release

Open Label Application Filed / Trial Progress

Date: April 1, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that it has received a Screening Acceptance Letter from Health Canada regarding a CTA filing for an open-label extension study of Tectin™ in patients with moderate to severe cancer-related pain. Approval for trial commencement is expected by April 9, 2004 .

This study is a long-term continuation of the Phase IIb/III multicentre, double-blind, placebo-controlled trial. The purpose of the open-label trial is to make Tectin™ available to all patients who participate in the Phase IIb/III study, thereby allowing them to benefit from continued treatment while providing the company with data on the long-term safety and efficacy of the product.

The Phase IIb/III is now actively ongoing following the Investigator's Meeting in January with representatives from more than 25 clinical sites. The recruitment is expected to start shortly as the process of obtaining Ethics Committee approval advances.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.